

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Clinical Significance of Putative Cancer Stem Cells in Residual Cancer Cells After Chemoradiotherapy for Rectal Cancer

Koji Tanaka, Yasuhiro Inoue, Yuji Toiyama,
Keiichi Uchida, Chikao Miki and Masato Kusunoki

*Department of Gastrointestinal and Pediatric Surgery,
Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Mie
Japan*

1. Introduction

Cancer stem cells (CSC) seem to be resistant to conventional chemo- and radiation therapies when compared with non-CSCs. Conventional cytotoxic therapies initially shrink the bulk of a tumor, but fail to eradicate it, resulting in tumor recurrence. Treatment failure may in part be due to the resistance of CSCs to chemotherapy or radiotherapy (Baumann et al., 2008; Eyler & Rich, 2008).

Drug or radiation surviving cells (residual tumor cells following treatment) have been shown to contain a higher frequency of putative CSCs in a number of human malignancies. Bao et al. demonstrated that the population of cells enriched for glioma CSCs was dramatically increased by irradiation and that radioresistant gliomas showed an increased percentage of CD133 positive cells (Bao et al., 2006). Tsuchida et al showed that anti-cancer drug treatment increases the side-population fraction (considered CSCs) in cancer cell lines (Tsuchida et al., 2008).

Over the past decades, preoperative chemoradiotherapy (CRT) has been established as one approach in the multimodal treatment of several types of gastrointestinal malignancies. In rectal cancer, preoperative CRT followed by surgery has improved sphincter preservation, local pelvic control and survival of patients with locally advanced rectal cancer (Bosset et al., 2006; Guillem et al., 2005). However, disease recurrence (especially for distant metastases) remains the major cause of mortality in these patients (Collette et al., 2007; van den Brink et al., 2004).

In rectal cancer, tumor regression grading (TRG) following CRT was determined by quantifying the proportion of residual cancer cells to the stroma of the entire tumor bed on formalin-fixed paraffin embedded (FFPE) specimens. TRG or pathologic response has been shown to predict clinical outcome (disease recurrence or patient survival) of oesophageal (Brücher et al., 2006; Chirieac et al., 2005), gastric (Patel et al., 2007; Rohatgi et al., 2006), or rectal cancer (Rödel et al., 2005) in patients after preoperative CRT followed by surgery, rather than pre-CRT clinical stage. The amount of residual cancer cells after CRT seems to be predictive of disease recurrence and survival in relation to CRT resistance.

Therefore, we hypothesized that CRT decreased or eradicated non-CSCs, which are sensitive to CRT, while increasing the percentage of putative CSCs characteristic of CRT resistance in the population of residual cancer cells. Residual cancer cells following CRT may be expected to contain a higher frequency of putative CSCs expressing stem cell markers, compared to primary, non-CRT tumor cells.

To test this hypothesis, we investigated the expression of stem cell markers in post-CRT residual cancer cells on FFPE specimens using microdissection and real-time quantitative reverse transcription polymerase chain reaction (RT-PCR).

2. Microdissection and RNA isolation from FFPE specimens

2.1 Microdissection in FFPE specimens

Tumor specimens were fixed in 10% formaldehyde solution v/v and embedded in paraffin. FFPE specimens (10 μ m sections) were stained with nuclear fast red (Vector Laboratories, Inc., CA) and subsequently manually microdissected under microscope magnification (from $\times 5$ to $\times 10$). Residual cancer cells were isolated using a sterile blade and carefully collected with reference to hematoxylin and eosin sections, containing more than 70% cancer cells. Fibrotic tissue areas, necrotic cells, and non-neoplastic cells were identified.

2.2 RNA extraction from FFPE specimens

Microdissected samples were digested with proteinase K in lysis buffer containing Tris-HCl, EDTA, and sodium dodecyl sulfate as previously reported with minor modification (Bijwaard et al., 2001). RNA was purified using phenol and chloroform extraction. Isolated RNA was purified using ethanol precipitation. The concentration and quality of RNA was measured with UV absorbance at 260 nm and 280 nm (A₂₆₀/A₂₈₀ ratio).

3. Expression of stem cell markers in residual cancer cells after CRT

3.1 cDNA synthesis

To reverse transcribe the fragmented mRNA from FFPE tissue materials, we used random hexamer priming, instead of oligo (dT)-based priming. cDNA was synthesized with random hexamer and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.

3.2 Real-time quantitative RT-PCR

Real-time quantitative RT-PCR analysis was performed using a fluorescence-based real-time detection method (TaqMan) and an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Inc., Foster City, CA). Although SYBR-Green based detection is less specific than TaqMan-based detection, we used SYBR-Green based detection to save experimental time and costs.

Primers were strictly selected or designed to be intron spanning to avoid amplification from contaminated genomic DNA. Target sequences were kept as small as possible (approximately 100 bp) to ensure the detection of fragmented and partially degraded RNA. To confirm primer specificity, a single band of expected amplicon size for each target gene was verified using gel electrophoresis on a 2% agarose gel and visualized with ethidium bromide.

Primers for CD133, CD44, OCT4, SOX2, VEGF, and beta actin were designed with primer3 software (Biology Workbench Version 3.2, San Diego Supercomputer Center, at the University of California, San Diego). Primers for EGFR were synthesized according to previously published sequences (Schneider et al., 2005). Primer sequences are shown in Table 1. PCR was performed in a final volume of 25 µl with a SYBR Green PCR Master Mix using 1 µl cDNA, and 400 nM of each primer for the respective genes. Cycling conditions were 50°C for 2 min and 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min.

gene	primer	sequence	product size
CD133	Forward	5'-GCTTTGCAATCTCCCTGTTG-3'	94bp
	Reverse	5'-TTGATCCGGGTTCTTACCTG-3'	
CD44	Forward	5'-CGGACACCATGGACAAGTTT-3'	115bp
	Reverse	5'-CACGTGGAATACACCTGCAA-3'	
OCT-4	Forward	5'-CTGGAGAAGGAGAAGCTGGA-3'	79bp
	Reverse	5'-CAAATTGCTCGAGTTCTTTCTG-3'	
SOX2	Forward	5'-CAAGATGCACAACCTCGGAGA-3'	95bp
	Reverse	5'-GCTTAGCCTCGTCGATGAAC-3'	
VEGF	Forward	5'-CAGAAGGAGGAGGGCAGAA-3'	80bp
	Reverse	5'-CTCGATTGGATGGCAGTAGC-3'	
EGFR	Forward	5'-CCTATGTGCAGAGGAATTATGATCTTT-3'	88bp
	Reverse	5'-CCACTGTGTTGAGGGCAATG-3'	
Beta actin	Forward	5'-ACAGAGCCTCGCCTTTGC-3'	75bp
	Reverse	5'-GCGGCGATATCATCATCC-3'	

Table 1. Primer sequences of target genes

3.3 Relative mRNA levels of target genes

The parameter Ct (threshold cycle) is defined as the fractional cycle number at which the fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. The Ct is inversely proportional to the amount of cDNA, i.e., a higher Ct value means that more PCR cycles are required to reach a certain level of detection.

Relative mRNA levels were determined by the standard curve method. Standard curves and line equations were generated using five-fold serially diluted solutions of cDNA from colon cancer cell line, Lovo. All standard curves were linear in the analyzed range with an acceptable correlation coefficient (R²). Target gene expression was calculated using the standard curve.

Quantitative normalization of cDNA in each sample was performed using the expression of the beta actin gene as an internal control. Finally, mRNA levels of the target gene were presented as ratios between the genes of interest and the internal reference gene (beta actin). Real-time PCR assays were performed twice for each sample and mean values were used for calculations of mRNA levels.

4. Difference in gene expression profile of primary tumor and residual tumor following CRT

4.1 Correlations of CD133, SOX2 and OCT4 mRNA levels in pre-CRT or post-CRT tumor cells

A cell surface protein CD133, known as prominin-1, has been regarded as one of the most important markers of colorectal CSCs (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). OCT4 and SOX2 are essential transcription factors for normal pluripotent cell development and maintenance in embryonic stem (ES) cells, which are also known as reprogramming genes that induce an ES cell-like state in fibroblasts i.e., induced pluripotent stem (iPS) cells (Takahashi et al., 2007; Yamanaka, 2008).

As shown in Fig.1-1, we examined how these 'stem cell' related genes were correlated in primary non-treated tumor cells and post-CRT residual tumor cells. A positive correlation between OCT4 and SOX2 was observed in pre-CRT endoscopic tumor specimens. There was no correlation between CD133 and OCT4 or SOX2 in pre-CRT specimens. In post-CRT residual cancer on FFPE specimens (Fig. 1-2), significant positive correlations among all three stem cell markers were seen (Saigusa et al., 2009).




Fig. 1-1 Correlation between CD133, SOX2 and OCT4 in pre-CRT tumor biopsy specimens




Fig. 1-2 Correlation between CD133, SOX2 and OCT4 in post-CRT residual cancer cells

Strong co-expression of OCT4 and SOX2 in both pre-and post-CRT tumor cells may indicate that these two genes have an indistinguishable relationship associated with maintenance of pluripotency in stem cells.

Also, residual cancer cells surviving CRT may enrich a population of putative CSCs expressing CD133, OCT4 and SOX2 because of the potential association between CSCs and treatment resistance.

4.2 Correlations of CD133, VEGF and EGFR mRNA levels in pre-CRT or post-CRT tumor cells

The vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways are closely associated with each other, and share common downstream signaling, especially for tumor angiogenesis. Increased expression of VEGF or EGFR has been reported to be involved in tumor aggressiveness, metastasis, and poor prognosis in several types of malignancies (Galizia et al., 2004; Galizia et al., 2006). To date, anti-VEGF and anti-EGFR antibodies have become indispensable in the treatment of metastatic CRC (Chau & Cunningham, 2009). In other words, both VEGF and EGFR are important therapeutic targets in CRC.

We then examined how CD133 correlated with these therapeutic targets for CRC in primary tumor and post-CRT residual tumor cells. There were significant positive correlations between CD133 and VEGF, between CD133 and EGFR or between VEGF and EGFR in pre-

CRT tumor biopsy specimens (Fig. 2-1). However, these correlations were not observed in post-CRT FFPE specimens (Fig. 2-2; Yasuda et al., 2009). We previously described several possibilities for explaining these findings. We believe it seems plausible that CRT may cause an imbalance between two distinct populations (putative CSCs and non-CSCs) within the tumor. A majority of tumor cells expressing VEGF and EGFR (considered as non-CSCs) may respond to CRT and then shrink or disappear. By contrast, a very small population of tumor cells expressing CD133 (considered as CSCs) may resist CRT and be left as residual cancer cells in post-CRT specimens.

4.3 CD133 and CD44 expression in pre-CRT or post-CRT tumor cells

CD44 is a transmembrane glycoprotein molecule, which is widely expressed as a cell surface hyaluronan receptor in normal epithelial, mesenchymal and hematopoietic cells. Also, CD44 has been reported as one of the important cell surface markers for isolating colorectal CSCs (Du et al., 2008; Haraguchi et al., 2008). We examined whether the expression of potential markers (CD133 and CD44) for colorectal CSCs were changed during CRT. As shown in Fig. 3, tumoral CD133 mRNA levels were significantly increased in post-CRT resected specimens, compared with pre-CRT biopsy specimens. By contrast, tumoral CD44 mRNA levels were significantly decreased in residual cancer cells from post-CRT resected specimens (Yasuda H et al., 2009).




Fig. 2-1 Correlation between CD133, VEGF and EGFR in pre-CRT tumor biopsy specimens




Fig. 2-2 Correlation between CD133, VEGF and EGFR in post-CRT residual cancer cells




Fig. 3. CD133 and CD44 expression in paired pre-and post-CRT specimens

The comparison of potential surface markers for colorectal CSCs between pre-CRT and post-CRT tumor cells indicate that changes in expression of CD133 and CD44 during CRT were

quite opposite. We speculate that residual cancer following CRT may contain more CSCs than primary tumors before CRT. The relative proportion of CSCs may increase in residual cancer following CRT. Thus, gene expression related to CSCs may also increase in residual cancer following CRT, compared with primary tumors. In this context, CD133 seemed preferable to CD44 as the marker for colorectal CSCs.

5. Radiation surviving cells *in vitro* and residual cancer cells after CRT

5.1 CD133 and CD44 in radiation surviving HT-29 cells *in vitro*

We performed an *in vitro* experiment using human colorectal cancer cell lines to determine whether irradiation itself can induce the expression of CD133 or CD44. Exponentially growing colorectal cells of the HT29 cell line were plated on a 10 cm dish and irradiated at a dose of 1, 2.5, and 5 Gy (CAX-150-20, Chubu medical Co. Ltd). Fourteen days later, colony formation assays were performed to evaluate cell survival after irradiation. Approximately 23%, 7%, and 5% survival fraction were found following irradiation with 1.0, 2.5, and 5.0 Gy, respectively. These surviving cells were collected for western blotting analysis. Single dose of 2.5 Gy and 5 Gy radiation increased CD133 protein levels, compared with control (Fig. 4-1). Densitometric analysis showed that CD133 was 1.4 times increased at 5 Gy radiation with respect to control. By contrast, radiation decreased CD44 protein levels regardless of radiation dose.




Fig. 4-1 CD133 and CD44 in radiation surviving HT-29 cells *in vitro*

CD133 increased in a radiation-dose dependent manner, despite the decreased number of radiation-surviving HT-29 cells. These *in vitro* results were consistent with CD133 mRNA levels increasing in residual cancer cells after CRT, compared with primary tumor cells before CRT. These results suggest that CRT may enrich the relative proportion of CD133 expressing CSCs within residual cancer, or that CRT may induce the expression of CD133 in tumor cells, or both.

5.2 Immunoreactive CD133 and CD44 in residual cancer cells after CRT

For immunohistochemical analysis, CD133 rabbit monoclonal antibody (Cell Signaling Technology, Inc. Boston, MA) and CD44 mouse monoclonal antibody (R&D Systems, Inc. Minneapolis, MN) were used. The primary antibody was detected using Envision reagents (Envision kit/HRP, Dako Cytomation, Denmark).

Immunoreactive CD133 and CD44 expression were observed in the minority of residual cancer cells within entire residual tumors (Fig. 4-2). There was no obvious concordance between CD133 and CD44 positivity of residual cancer cells, which may support the notion that CD133 positive and CD44 positive cells did not colocalize in colorectal cancer specimens (Du et al., 2008).




Fig. 4-2 Immunoreactive CD133 and CD44 in residual cancer cells after CRT

CD133 immunostaining in residual cancer cells after CRT showed not only apical/endoluminal membranous staining, but also cytoplasmic staining. Immervoll et al reported that apical/endoluminal membranous CD133 staining was characteristic by well-oriented, polarized and differentiated cells, while cytoplasmic CD133 staining was found in a minor population of cells (Immervoll et al., 2008). We have previously reported that residual cancer cells after CRT showed strong CD133 and moderate OCT4 and SOX2 staining, but no CK20 staining (a known epithelial marker) was observed (Saigusa et al., 2009). These lines of evidence suggest that CRT may induce dedifferentiation of cancer cells or may select putative CSCs with undifferentiated phenotype.

To determine if CRT may increase the relative proportion of CD133 expressing CSCs within residual cancer, it is necessary to compare the number of CD133 expressing tumor cells in pre-CRT endoscopic biopsy specimens and post-CRT resected specimens. This study has not yet been completed.

6. Clinical significance of CD133, OCT4, and SOX2 expression on residual cancer cells in patients with rectal cancer

6.1 Association of post-CRT CD133, CD44, OCT4, and SOX2 expression with clinicopathological variables

Thirty-three patients undergoing CRT followed by surgery were analyzed for an association between post-CRT OCT4 and SOX2 expression with clinical outcome. A total of 52 patients were analyzed for an association of post-CRT CD133 and CD44 expression with clinical outcome.

Patients who developed distant metastatic recurrence (e.g. liver, lung) had a significantly higher post-CRT CD133, OCT4, and SOX2 compared with those patients without recurrence. No such relationship was observed for post-CRT CD44.

6.2 Association of post-CRT CD133, CD44, OCT4, and SOX2 expression with patient survival

To identify the cut-off values of CD133, CD44, OCT4, and SOX2 predictive of distant metastatic recurrence, receiver operating curve (ROC) analysis was used. As shown in Fig. 5, patients with post-CRT CD133, OCT4, and SOX2 above cut-off value ('High') showed significantly worse disease free survival, compared with those with 'Low'. No such relationship was observed for post-CRT CD44.




Fig. 5. Kaplan-Meier plots of disease free survival according to post-CRT CD133, CD44, SOX2, and OCT4 expression

Introduction of preoperative CRT followed by surgery (total mesorectal excision) in the management of rectal cancer significantly decreased local recurrence rate and improved patients' survival. However, the rate of distant metastatic recurrence still remains as high as 15-20% of rectal cancer treated with preoperative CRT followed by TME (Guillem et al., 2005). Identifying predictive markers for disease recurrence or poor prognosis of such patients is urgently required for appropriate treatment stratification. Our results suggest that the expression of 'stem cell' genes such as CD133, OCT4 and SOX2 on post-CRT residual cancer cells may predict metachronous distant metastasis and poor prognosis of rectal cancer patients treated with preoperative CRT followed by surgery.

7. Clinical significance of residual cancer cells after CRT as putative colorectal CSCs

7.1 The proportion of putative CSCs in primary tumors

The presence of CSCs in primary tumors seems to be of prognostic significance for several malignancies (Liu et al., 2007; Zeppernick et al., 2008). In primary colorectal cancer, CD133 expression has also been reported to be a significant prognostic marker (Horst et al., 2008; Kojima et al., 2008). This may indicate that the proportion of CD133 expressing CSCs in primary, non-treatment tumor might be predictive for less treatment efficacy, more chance of disease recurrence, and poor prognosis of CRC patients.

In this study, the expression of CD133, CD44 SOX2, and OCT4 in pre-CRT primary tumor did not correlate with disease recurrence or survival of rectal cancer patients (data not shown). Since we had only 30 pre-CRT endoscopic tumor biopsies available, our data should be interpreted with caution. However, post-CRT, but not pre-CRT CD133, SOX2, and OCT4 has shown to be associated with metachronous distant metastasis and poor prognosis of rectal cancer patients treated with preoperative CRT followed by surgery.

7.2 The proportion of putative CSCs in post-treatment residual tumors

According to the CSC hypothesis, CRT surviving cancer cells (residual cancer cells following CRT) should contain a higher frequency of CRT-resistant colorectal CSCs, compared with primary, pre-CRT cancer cells. Our correlation results between pre-CRT or post-CRT CD133, SOX2, OCT4, VEGF, and EGFR, show that CRT may eliminate a majority of cancer cells expressing VEGF or EGFR (considered non-CSCs with CRT sensitive phenotype), and may leave a small population of cancer cells expressing CD133, OCT4, or SOX2 (considered CSCs with CRT resistant phenotype).

Although we think that residual cancer cells are not completely identical to CSCs, our results suggest that the relative proportion of putative CSCs expressing CD133, OCT4, or SOX2 may increase in post-CRT residual cancer cells in FFPE specimens, compared with pre-CRT primary tumor cells. Our findings are consistent with recent experiments (Dallas et al., 2009; Dylla et al., 2008).

7.3 CD133 and CD44 as potential markers for colorectal CSCs

Both CD133 and CD44 are of functional importance as potential cell surface markers for colorectal CSC. It still remains to be resolved if either CD133 or CD44 could be clinically important in CRT surviving cells, or if CRT can increase the expression of these markers. In pre- and post-CRT paired specimens, significant increase in tumoral CD133 and significant decrease in tumoral CD44 was observed. *In vitro*, CD133, but not CD44 was increased in radiation-resistant surviving colorectal cancer cell lines (HT29 cells).

CD133 seemed preferable to CD44 as the marker of colorectal CSCs according to the notion that CRT may increase the relative proportion of CSCs which express the potential markers of colorectal CSCs.

8. Conclusion

The proportion of CSCs in residual tumors following preoperative CRT may be more accurately predictive for less treatment efficacy, more chance of disease recurrence, and poor prognosis of rectal cancer patients than the proportion of CSCs in non-pretreatment

primary tumor. Expression of the potential markers of colorectal CSCs in microdissected residual cancer on FFPE specimens may provide useful information regarding treatment stratification and clinical management of rectal cancer patients after CRT and surgery.

9. References

- [1] Bao S et al. (December 2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature*. Vol.444, No.7120, pp. 756-760, ISSN 1476-4687
- [2] Baumann M et al. (July 2008). Exploring the role of cancer stem cells in radioresistance. *Nat Rev Cancer*. Vol.8, No.7, pp. 545-554, ISSN 1474-1768
- [3] Bijwaard KE et al. (February 2001). Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. *Clin Chem*. Vol.47, No.2, pp. 195-201, ISSN 0009-9147
- [4] Bosset JF et al. (September 2006). Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med*. Vol.355, No.11, pp. 1114-1123, ISSN 1533-4406
- [5] Brücher BL et al. (May 2006). The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. *Cancer*. Vol.106, No.10, pp. 2119-2127, ISSN 0008-543X
- [6] Chau I & Cunningham D. (June 2009). Treatment in advanced colorectal cancer: what, when and how? *Br J Cancer*. Vol.100, No.11, pp. 1704-1719, ISSN 1532-1827
- [7] Chirieac LR et al. (April 2005). Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. *Cancer*. Vol.103, No.7, pp. 1347-1355, ISSN 0008-543X
- [8] Collette L et al. (October 2007). Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. *J Clin Oncol*. Vol.25, No.28, pp. 4379-4386, ISSN 1527-7755
- [9] Dallas NA et al. (March 2009). Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. *Cancer Res*. Vol.69, No.5, pp. 1951-1957, ISSN 1538-7445
- [10] Du L et al. (November 2008). CD44 is of functional importance for colorectal cancer stem cells. *Clin Cancer Res*. Vol.14, No.21, pp. 6751-6760, ISSN 1078-0432
- [11] Dylla SJ et al. (June 2008). Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. *PLoS One*. Vol.3, No.6, pp. e2428, ISSN 1932-6203
- [12] Eyler CE & Rich JN. (June 2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. *J Clin Oncol*. Vol.26, No.17, pp. 2839-2845, ISSN 1527-7755
- [13] Galizia G et al. (May 2004). Determination of molecular marker expression can predict clinical outcome in colon carcinomas. *Clin Cancer Res*. Vol.15, No.10, pp. 3490-3499, ISSN 1078-0432
- [14] Galizia G et al. (June 2006). Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. *Ann Surg Oncol*. Vol.13, No.6, pp. 823-835, ISSN 1068-9265

- [15] Guillem JG et al. (May 2005). Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. *Ann Surg* Vol.241, No.5, pp. 829-836, ISSN 0003-4932
- [16] Haraguchi N et al. (October 2008). CD133+CD44+ population efficiently enriches colon cancer initiating cells. *Ann Surg Oncol*. Vol.15, No.10, pp. 2927-2933, ISSN 1534-4681
- [17] Horst D et al. (October 2008). CD133 expression is an independent prognostic marker for low survival in colorectal cancer. *Br J Cancer*. Vol.99, No.8, pp. 1285-1289, ISSN 1532-1827
- [18] Immervoll H et al. (February 2008). Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. *BMC Cancer* Vol.8, pp. 48, ISSN 1471-2407
- [19] Kojima M et al. (August 2008). Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. *Cancer Sci*. Vol.99, No.8, pp. 1578-1583, ISSN 1349-7006
- [20] Liu R et al. (January 2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. *N Engl J Med*. Vol.356, No.3, pp. 217-226, ISSN 1533-4406
- [21] O'Brien CA et al. (January 2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature*. Vol.445, No.7123, pp. 106-110, ISSN 1476-4687
- [22] Patel PR et al. (September 2007). Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. *Cancer*. Vol.110, No.5, pp. 989-995, ISSN 0008-543X
- [23] Ricci-Vitiani L et al. (January 2007). Identification and expansion of human colon-cancer-initiating cells. *Nature*. Vol.445, No.7123, pp. 111-115, ISSN 1476-4687
- [24] Rohatgi PR et al. (October 2006). Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. *Cancer*. Vol.107, No.7, pp. 1475-1482, ISSN 0008-543X
- [25] Rödel C et al. (December 2005). Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol*. Vol.23, No.34, pp. 8688-8696, ISSN 0732-183X
- [26] Saigusa S et al. (December 2009). Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. *Ann Surg Oncol*. Vol.16, No.12, pp. 3488-3498, ISSN 1534-4681
- [27] Schneider S et al. (March 2005). Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. *J Am Coll Surg*. Vol.200, No.3, pp. 336-344, ISSN 1072-7515
- [28] Takahashi K et al. (November 2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* Vol.131, No.5, pp. 861-872, ISSN 0092-8674
- [29] Tsuchida R et al. (June 2008). Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. *Oncogene*. Vol.27, No.28, pp. 3923-3934, ISSN 1476-5594
- [30] van den Brink M et al. (October 2004). Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. *J Clin Oncol*. Vol.22, No.19, pp. 3958-3964, ISSN 0732-183X

- [31] Yamanaka S. (February 2008). Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. *Cell Prolif.* Vol.41, No.Suppl 1, pp. 51-56, ISSN 1365-2184
- [32] Yasuda H et al. (October 2009). Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. *Oncol Rep.* Vol.22, No.4, pp. 709-717, ISSN 1021-335X
- [33] Zeppernick F et al. (January 2008). Stem cell marker CD133 affects clinical outcome in glioma patients. *Clin Cancer Res.* Vol.14, No.1, pp. 123-129, ISSN 1078-0432



Cancer Stem Cells - The Cutting Edge

Edited by Prof. Stanley Shostak

ISBN 978-953-307-580-8

Hard cover, 606 pages

Publisher InTech

Published online 01, August, 2011

Published in print edition August, 2011

Over the last thirty years, the foremost inspiration for research on metastasis, cancer recurrence, and increased resistance to chemo- and radiotherapy has been the notion of cancer stem cells. The twenty-eight chapters assembled in *Cancer Stem Cells - The Cutting Edge* summarize the work of cancer researchers and oncologists at leading universities and hospitals around the world on every aspect of cancer stem cells, from theory and models to specific applications (glioma), from laboratory research on signal pathways to clinical trials of bio-therapies using a host of devices, from solutions to laboratory problems to speculation on cancers' stem cells' evolution. Cancer stem cells may or may not be a subset of slowly dividing cancer cells that both disseminate cancers and defy oncotoxic drugs and radiation directed at rapidly dividing bulk cancer cells, but research on cancer stem cells has paid dividends for cancer prevention, detection, targeted treatment, and improved prognosis.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Koji Tanaka, Yasuhiro Inoue, Yuji Toiyama, Keiichi Uchida, Chikao Miki and Masato Kusunoki (2011). Clinical Significance of Putative Cancer Stem Cells in Residual Cancer Cells After Chemoradiotherapy for Rectal Cancer, *Cancer Stem Cells - The Cutting Edge*, Prof. Stanley Shostak (Ed.), ISBN: 978-953-307-580-8, InTech, Available from: <http://www.intechopen.com/books/cancer-stem-cells-the-cutting-edge/clinical-significance-of-putative-cancer-stem-cells-in-residual-cancer-cells-after-chemoradiotherapy>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen